Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial

医学 瑞舒伐他汀 阿托伐他汀 危险系数 内科学 冠状动脉疾病 心肌梗塞 中止 随机对照试验 心脏病学 置信区间 外科
作者
Yong‐Joon Lee,Sung‐Jin Hong,Woong Chol Kang,Bum‐Kee Hong,Jong‐Young Lee,Jin‐Bae Lee,Hyung-Jin Cho,Junghan Yoon,Seung‐Jun Lee,Chul‐Min Ahn,Jung‐Sun Kim,Byeong‐Keuk Kim,Young–Guk Ko,Donghoon Choi,Yangsoo Jang,Myeong‐Ki Hong
标识
DOI:10.1136/bmj-2023-075837
摘要

To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease.Randomised, open label, multicentre trial.12 hospitals in South Korea, September 2016 to November 2019.4400 adults (age ≥19 years) with coronary artery disease.Participants were assigned to receive either rosuvastatin (n=2204) or atorvastatin (n=2196) using 2×2 factorial randomisation.The primary outcome was a three year composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation. Secondary outcomes were safety endpoints: new onset diabetes mellitus; hospital admissions due to heart failure; deep vein thrombosis or pulmonary thromboembolism; endovascular revascularisation for peripheral artery disease; aortic intervention or surgery; end stage kidney disease; discontinuation of study drugs owing to intolerance; cataract surgery; and a composite of laboratory detected abnormalities.4341 of the 4400 participants (98.7%) completed the trial. Mean daily dose of study drugs was 17.1 mg (standard deviation (SD) 5.2 mg) in the rosuvastatin group and 36.0 (12.8) mg in the atorvastatin group at three years (P<0.001). The primary outcome occurred in 189 participants (8.7%) in the rosuvastatin group and 178 (8.2%) in the atorvastatin group (hazard ratio 1.06, 95% confidence interval 0.86 to 1.30; P=0.58). The mean low density lipoprotein (LDL) cholesterol level during treatment was 1.8 mmol/L (SD 0.5 mmol/L) in the rosuvastatin group and 1.9 (0.5) mmol/L in the atorvastatin group (P<0.001). The rosuvastatin group had a higher incidence of new onset diabetes mellitus requiring initiation of antidiabetics (7.2% v 5.3%; hazard ratio 1.39, 95% confidence interval 1.03 to 1.87; P=0.03) and cataract surgery (2.5% v 1.5%; 1.66, 1.07 to 2.58; P=0.02). Other safety endpoints did not differ between the two groups.In adults with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy for the composite outcome of all cause death, myocardial infarction, stroke, or any coronary revascularisation at three years. Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery compared with atorvastatin.ClinicalTrials.gov NCT02579499.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Blue发布了新的文献求助10
刚刚
失眠的夜梦完成签到,获得积分10
2秒前
谓风完成签到,获得积分10
3秒前
恋雅颖月应助乐观的寻绿采纳,获得10
3秒前
Shrine完成签到,获得积分10
3秒前
英姑应助紫色奶萨采纳,获得10
5秒前
6秒前
7秒前
希望天下0贩的0应助Jay采纳,获得10
8秒前
8秒前
爆米花应助zewangguo采纳,获得10
9秒前
斯文败类应助loong采纳,获得10
10秒前
深情安青应助Xin采纳,获得10
11秒前
和花花发布了新的文献求助10
11秒前
摩卡完成签到,获得积分10
12秒前
13秒前
14秒前
端庄毛巾完成签到,获得积分10
14秒前
15秒前
15秒前
15秒前
张雯思发布了新的文献求助10
17秒前
ding应助Nugget采纳,获得10
17秒前
幸福大白发布了新的文献求助30
20秒前
wdy111举报ZZZ求助涉嫌违规
21秒前
zewangguo发布了新的文献求助10
21秒前
22秒前
高大的冰双完成签到,获得积分10
23秒前
25秒前
987完成签到 ,获得积分10
26秒前
loong完成签到,获得积分10
26秒前
紫色奶萨发布了新的文献求助10
27秒前
zewangguo完成签到,获得积分10
27秒前
28秒前
如意手链完成签到,获得积分10
29秒前
DongWei95发布了新的文献求助30
30秒前
锦诗完成签到,获得积分10
31秒前
isojso发布了新的文献求助10
32秒前
33秒前
科研通AI2S应助科研通管家采纳,获得10
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174